C12P17/186

FERMENTATION PROCESS
20230235375 · 2023-07-27 ·

The present invention is related to sustainable fermentation processes with increased efficiency and less environmental impact. Particularly, the present invention is related to a process wherein in one fermentation process two or more fermentation products can be produced and isolated, i.e. a “primary” fermentation product and a “secondary” fermentation product, particularly wherein one is a water soluble organic compound and one is a fat-soluble organic compound particularly a fat-soluble vitamin, preferably vitamin K2.

Hybrid polyketide synthases

The present invention provides for a polyketide synthase (PKS) capable of synthesizing an even-chain or odd-chain diacid or lactam or diamine. The present invention also provides for a host cell comprising the PKS and when cultured produces the even-chain diacid, odd-chain diacid, or KAPA. The present invention also provides for a host cell comprising the PKS capable of synthesizing a pimelic acid or KAPA, and when cultured produces biotin.

BIOTIN SYNTHASES FOR EFFICIENT PRODUCTION OF BIOTIN
20220348974 · 2022-11-03 ·

A recombinant microorganism includes a transgene encoding a polypeptide of a Type II biotin synthase, wherein a holo-protein of the Type II biotin synthase comprises per polypeptide chain a first [4Fe—4S] cluster (radical SAM (RS) cluster) coordinated to a CxxxCxxC motif in the polypeptide chain and a second [4Fe—4S] cluster. The Type II biotin synthase contains a serine to cysteine swap in its holo-protein amino acid sequence, that is the amino acid at the position corresponding to Ser-43 in the E. coli K12 Type I biotin synthase holo-protein is a Cysteine and the amino acid corresponding to Cys-97 in the E. coli K12 Type I biotin synthase holo-protein is a Serine. A method for producing biotin includes cultivating the recombinant microorganism in a growth medium to produce a culture; and recovering biotin from the culture.

CELL FACTORY HAVING IMPROVED IRON-SULFUR CLUSTER DELIVERY

The invention provides a genetically modified bacterial cell capable of improved iron-sulfur cluster delivery, characterized by a modified gene encoding a mutant Iron Sulfur Cluster Regulator (IscR) as well as one or more transgenes encoding polypeptides that enhance the biosynthesis of either biotin, lipoic acid or thiamine. The invention provides a method for producing either biotin, lipoic acid or thiamine using the genetically modified bacterium of the invention; as well as for the use of the genetically modified bacterial cell for either biotin, lipoic acid or thiamine production.

Hybrid Polyketide Synthases

The present invention provides for a polyketide synthase (PKS) capable of synthesizing an even-chain or odd-chain diacid or lactam or diamine. The present invention also provides for a host cell comprising the PKS and when cultured produces the even-chain diacid, odd-chain diacid, or KAPA. The present invention also provides for a host cell comprising the PKS capable of synthesizing a pimelic acid or KAPA, and when cultured produces biotin.

Hybrid polyketide synthases

The present invention provides for a polyketide synthase (PKS) capable of synthesizing an even-chain or odd-chain diacid or lactam or diamine. The present invention also provides for a host cell comprising the PKS and when cultured produces the even-chain diacid, odd-chain diacid, or KAPA. The present invention also provides for a host cell comprising the PKS capable of synthesizing a pimelic acid or KAPA, and when cultured produces biotin.

MICROBIAL CELL FACTORIES PRODUCING VITAMIN B COMPOUNDS

The present disclosure relates to a genetically modified host cell having increased production of one or more vitamin B compounds, wherein the host cell is genetically modified by mutating one or more native polynucleotide constructs for reducing formation of a CRP-cAMP complex in the host cell and/or introducing one or more genetic alterations increasing the degradation and/or non-CRP binding of cAMP in the host cell; whereby the production of the vitamin B compound in the genetically modified host cell is increased compared to a parent host cell.

NEOSORAPHENS

The present invention relates to compounds according to general formula (I); to compositions, including a pharmaceutical formulation and a combination preparation comprising one or more of the compound (s); to a process for their preparation; to uses thereof, including the use in the treatment or prevention of a viral infection or a Th17-associated inflammatory and/or autoimmune disease.

##STR00001##

HYBRID POLYKETIDE SYNTHASES

The present invention provides for a polyketide synthase (PKS) capable of synthesizing an even-chain or odd-chain diacid or lactam or diamine. The present invention also provides for a host cell comprising the PKS and when cultured produces the even-chain diacid, odd-chain diacid, or KAPA. The present invention also provides for a host cell comprising the PKS capable of synthesizing a pimelic acid or KAPA, and when cultured produces biotin.